• 四川大學(xué)華西醫(yī)院肝臟外科及肝臟移植中心（四川成都 610041）;

引用本文： 李波. 復(fù)發(fā)肝癌診治現(xiàn)狀及策略. 中國(guó)普外基礎(chǔ)與臨床雜志, 2013, 20(5): 469-473. doi: 復(fù)制

1. Llovet JM， Schwartz M， Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma[J]. Semin Liver Dis， 2005， 25(2)：181-200.
2. 叢文銘， 吳孟超. 肝癌術(shù)后復(fù)發(fā)發(fā)生機(jī)制及臨床病理學(xué)意義[J]. 中國(guó)實(shí)用外科雜志， 2012， 32(10)：809-811.
3. Kim MY， Oskarsson T， Acharyya S， et al. Tumor self-seeding by circulating cancer cells[J]. Cell， 2009， 139(7)：1315-1326.
4. Zhang Y， Li J， Cao L， et al. Circulating tumor cells in hepatocellular carcinoma：detection techniques， clinical implications， and future perspectives[J]. Semin Oncol， 2012， 39(4)：449-460.
5. Portolani N， Coniglio A， Ghidoni S， et al. Early and late recurrence after liver resection for hepatocellular carcinoma：prognosticand therapeutic implications[J]. Ann Surg， 2006， 243(2)：229-235.
6. 孫建， 簡(jiǎn)志祥， 區(qū)應(yīng)亮， 等. 肝癌根治性切除術(shù)后早期復(fù)發(fā)時(shí)限和模式的確定及其對(duì)預(yù)后的影響[J]. 實(shí)用醫(yī)學(xué)雜志， 2011， 27(10)：1748-1750.
7. Poon RT， Fan ST， Ng IO， et al. Significance of resection marginin hepatectomy for hepatocellular carcinoma：A critical reappraisal[J]. Ann Surg， 2000， 231(4)：544-551.
8. Kow AW， Kwon CH， Song S， et al. Risk factors of peritoneal recurrence and outcome of resected peritoneal recurrence after liver resection in hepatocellular carcinoma：review of 1 222 cases of hepatectomy in a tertiary institution[J]. Ann Surg Oncol， 2012， 19(7)：2246-2255.
9. Burak KW. Prognosis in the early stages of hepatocellular carci-noma：Predicting outcomes and properly selecting patients forcurative options[J]. Can J Gastroenterol， 2011， 25(9)：482-484.
10. Wu TH， Yu MC， Chen TC， et al. Encapsulation is a significant prognostic factor for better outcome in large hepatocellular carcinoma[J]. J Surg Oncol， 2012， 105(1)：85-90.
11. Lee CW， Chan KM， Lee CF， et al. Hepatic resection for hepatocellular carcinoma with lymph node metastasis：clinicopathological analysis and survival outcome[J]. Asian J Surg， 2011， 34(2)：53-62.
12. Ye JZ， Miao ZG， Wu FX， et al. Recurrence after anatomicresection versus nonanatomic resection for hepatocellular carcinoma：a meta-analysis[J]. Asian Pac J Cancer Prev， 2012， 13(5)：1771-1777.
13. Poon RT， Fan ST， Lo CM， et al. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitisB-related cirrhosis[J]. J Clin Oncol， 2000， 18(5)：1094-1101.
14. Tamura Y， Suda T， Arii S， et al. Value of highly sensitive fucos-ylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment[J]. Dig Dis Sci， 2013 Apr 18. [Epub ahead of print].
15. Shirakawa H， Suzuki H， Shimomura M， et al. Glypican-3 expre-ssion is correlated with poor prognosis in hepatocellular carcinoma[J]. Cancer Sci， 2009， 100(8)：1403-1407.
16. Chen IP， Ariizumi SI， Nakano M， et al. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy[J]. J Gastroenterol， 2013 Mar 27. [Epub ahead of print].
17. Ahn S， Hyeon J， Park CK. Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy[J]. Gut Liver， 2013， 7(2)：206-212.
18. Hyeon J， Ahn S， Lee JJ， et al. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma[J]. Dig Dis Sci， 2013 Mar 2. [Epub ahead of print].
19. Zhong JH， Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma：A meta-analysis[J]. Hepatol Res， 2010， 40(10)：943-953.
20. Peng BG， He Q， Li JP， et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Am J Surg， 2009， 198(3)：313-318.
21. Nitta H， Beppu T， Imai K， et al. Adjuvant hepatic arterial infusionchemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion[J]. World J Surg， 2013， 37(5)：1034-1042.
22. 廖錦岐， 袁波， 程玉， 等. 不同治療方法對(duì)肝癌術(shù)后復(fù)發(fā)的評(píng)價(jià)[J]. 中國(guó)醫(yī)藥科學(xué)， 2011， 19(1)：46-47.
23. Lau WY， Lai EC. Hepatocellular carcinoma：current management and recent advances[J]. Hepatobiliary Pancreat Dis Int， 2008， 7(3)：237-257.
24. Zhou YM， Sui CG， Li B， et al. Repeat hepatectomy for recurrent hepatocellular carcinoma：a local experience and a systematic review[J]. World J Surg Oncol， 2010， 8：55.
25. Chan DL， Morris DL， Chua TC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma－A systematic review[J]. Surg Oncol， 2013， pii：S0960-7404(13)00027-3. doi：10.1016/j.suronc.2013.02.009.
26. Hu Z， Wang W， Li Z， et al. Recipient outcomes of salvage liver transplantation versus primary liver transplantation：a systematic review and meta-analysis[J]. Liver Transpl， 2012， 18(11)：1316-1323.
27. Liu F， Yuan D， Wei YG， et al. Systematic review and meta-analysis of the relationship between EPHX1 polymorphisms and colorectal cancer risk[J]. Plos One， 2012， 7(8)：1-10.
28. 方河清， 唐酷， 何敏志. 射頻消融在復(fù)發(fā)性肝癌治療中的應(yīng)用[J]. 肝膽外科雜志， 2012， 20(4)：246-247.
29. 區(qū)應(yīng)亮， 孫建， 王慧玲， 等. 肝癌根治性切除術(shù)后早期復(fù)發(fā)的治療策略[J]. 廣東醫(yī)學(xué)， 2012， 33(5)：622-625.
  1. 1. Llovet JM， Schwartz M， Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma[J]. Semin Liver Dis， 2005， 25(2)：181-200.
  2. 2. 叢文銘， 吳孟超. 肝癌術(shù)后復(fù)發(fā)發(fā)生機(jī)制及臨床病理學(xué)意義[J]. 中國(guó)實(shí)用外科雜志， 2012， 32(10)：809-811.
  3. 3. Kim MY， Oskarsson T， Acharyya S， et al. Tumor self-seeding by circulating cancer cells[J]. Cell， 2009， 139(7)：1315-1326.
  4. 4. Zhang Y， Li J， Cao L， et al. Circulating tumor cells in hepatocellular carcinoma：detection techniques， clinical implications， and future perspectives[J]. Semin Oncol， 2012， 39(4)：449-460.
  5. 5. Portolani N， Coniglio A， Ghidoni S， et al. Early and late recurrence after liver resection for hepatocellular carcinoma：prognosticand therapeutic implications[J]. Ann Surg， 2006， 243(2)：229-235.
  6. 6. 孫建， 簡(jiǎn)志祥， 區(qū)應(yīng)亮， 等. 肝癌根治性切除術(shù)后早期復(fù)發(fā)時(shí)限和模式的確定及其對(duì)預(yù)后的影響[J]. 實(shí)用醫(yī)學(xué)雜志， 2011， 27(10)：1748-1750.
  7. 7. Poon RT， Fan ST， Ng IO， et al. Significance of resection marginin hepatectomy for hepatocellular carcinoma：A critical reappraisal[J]. Ann Surg， 2000， 231(4)：544-551.
  8. 8. Kow AW， Kwon CH， Song S， et al. Risk factors of peritoneal recurrence and outcome of resected peritoneal recurrence after liver resection in hepatocellular carcinoma：review of 1 222 cases of hepatectomy in a tertiary institution[J]. Ann Surg Oncol， 2012， 19(7)：2246-2255.
  9. 9. Burak KW. Prognosis in the early stages of hepatocellular carci-noma：Predicting outcomes and properly selecting patients forcurative options[J]. Can J Gastroenterol， 2011， 25(9)：482-484.
  10. 10. Wu TH， Yu MC， Chen TC， et al. Encapsulation is a significant prognostic factor for better outcome in large hepatocellular carcinoma[J]. J Surg Oncol， 2012， 105(1)：85-90.
  11. 11. Lee CW， Chan KM， Lee CF， et al. Hepatic resection for hepatocellular carcinoma with lymph node metastasis：clinicopathological analysis and survival outcome[J]. Asian J Surg， 2011， 34(2)：53-62.
  12. 12. Ye JZ， Miao ZG， Wu FX， et al. Recurrence after anatomicresection versus nonanatomic resection for hepatocellular carcinoma：a meta-analysis[J]. Asian Pac J Cancer Prev， 2012， 13(5)：1771-1777.
  13. 13. Poon RT， Fan ST， Lo CM， et al. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitisB-related cirrhosis[J]. J Clin Oncol， 2000， 18(5)：1094-1101.
  14. 14. Tamura Y， Suda T， Arii S， et al. Value of highly sensitive fucos-ylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment[J]. Dig Dis Sci， 2013 Apr 18. [Epub ahead of print].
  15. 15. Shirakawa H， Suzuki H， Shimomura M， et al. Glypican-3 expre-ssion is correlated with poor prognosis in hepatocellular carcinoma[J]. Cancer Sci， 2009， 100(8)：1403-1407.
  16. 16. Chen IP， Ariizumi SI， Nakano M， et al. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy[J]. J Gastroenterol， 2013 Mar 27. [Epub ahead of print].
  17. 17. Ahn S， Hyeon J， Park CK. Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy[J]. Gut Liver， 2013， 7(2)：206-212.
  18. 18. Hyeon J， Ahn S， Lee JJ， et al. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma[J]. Dig Dis Sci， 2013 Mar 2. [Epub ahead of print].
  19. 19. Zhong JH， Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma：A meta-analysis[J]. Hepatol Res， 2010， 40(10)：943-953.
  20. 20. Peng BG， He Q， Li JP， et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Am J Surg， 2009， 198(3)：313-318.
  21. 21. Nitta H， Beppu T， Imai K， et al. Adjuvant hepatic arterial infusionchemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion[J]. World J Surg， 2013， 37(5)：1034-1042.
  22. 22. 廖錦岐， 袁波， 程玉， 等. 不同治療方法對(duì)肝癌術(shù)后復(fù)發(fā)的評(píng)價(jià)[J]. 中國(guó)醫(yī)藥科學(xué)， 2011， 19(1)：46-47.
  23. 23. Lau WY， Lai EC. Hepatocellular carcinoma：current management and recent advances[J]. Hepatobiliary Pancreat Dis Int， 2008， 7(3)：237-257.
  24. 24. Zhou YM， Sui CG， Li B， et al. Repeat hepatectomy for recurrent hepatocellular carcinoma：a local experience and a systematic review[J]. World J Surg Oncol， 2010， 8：55.
  25. 25. Chan DL， Morris DL， Chua TC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma－A systematic review[J]. Surg Oncol， 2013， pii：S0960-7404(13)00027-3. doi：10.1016/j.suronc.2013.02.009.
  26. 26. Hu Z， Wang W， Li Z， et al. Recipient outcomes of salvage liver transplantation versus primary liver transplantation：a systematic review and meta-analysis[J]. Liver Transpl， 2012， 18(11)：1316-1323.
  27. 27. Liu F， Yuan D， Wei YG， et al. Systematic review and meta-analysis of the relationship between EPHX1 polymorphisms and colorectal cancer risk[J]. Plos One， 2012， 7(8)：1-10.
  28. 28. 方河清， 唐酷， 何敏志. 射頻消融在復(fù)發(fā)性肝癌治療中的應(yīng)用[J]. 肝膽外科雜志， 2012， 20(4)：246-247.
  29. 29. 區(qū)應(yīng)亮， 孫建， 王慧玲， 等. 肝癌根治性切除術(shù)后早期復(fù)發(fā)的治療策略[J]. 廣東醫(yī)學(xué)， 2012， 33(5)：622-625.

  • 下一篇

    從汶川至蘆山：地震醫(yī)療救援投入產(chǎn)出效益評(píng)估